Shire Launches 2016 Excellence in ADHD Patient Group Awards

Online entry opens today at
https://www.shire.com/patients/patient-advocacy/patient-group-award

ZUG, Switzerland – June 15, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today launches the third annual Excellence in ADHD Patient Group Awards celebrating outstanding work by patient advocacy organisations around the world that aim to improve the lives of people with Attention Deficit/Hyperactivity Disorder (ADHD). Three winning patient groups will each be awarded an unrestricted grant of €10,000 to recognise their exceptional work in 2015.

“We are extremely proud of the Excellence in ADHD programme at Shire,” says Tom Croce, Head of Global Patient Advocacy at Shire. “The number of award entries has grown year on year as more patient groups in more countries are showcasing the differences they are making to patients’ lives and we expect the 2016 awards programme to be the most subscribed to date. We have already awarded €60,000 to patient advocacy groups through the programme recognising the outstanding work they do to support ADHD sufferers and I am looking forward to reading all of the entries this year."

The awards are open to patient organisations based outside of the USA with not-for-profit/charitable status that put the needs and interests of people affected by ADHD at the heart of their work.

An independent international judging panel with expertise across patient advocacy and mental health will select three winners according to strict judging criteria. The 2016 judges are:

• Ann Little – President, European Federation of Neurological Associations
• Frédéric Destrebecq – Executive Director, European Brain Council
• Kawaldip Sehmi – Chief Executive Officer, International Alliance of Patients’ Organizations

"We were delighted to have been selected as one of the winners for the Excellence in ADHD Patient Group Awards 2015,” said one of last year’s three winners Alison Clink, Project Manager of The Dundee and Angus ADHD Support Group. "Receiving the grant has been instrumental in allowing us to provide additional services which have had a positive impact on the needs of our children and their parents – we have been able to provide training workshops for our volunteers, we have enhanced the range of activities on offer as part of our holiday club and we are able to bring a regular speaker to our Parents’ Support Group. We would actively encourage all other ADHD patient groups to enter the awards.”

The judges are looking for projects that address unmet needs in ADHD and have a direct and positive impact on the lives of people affected by the disorder. Winning entries will have demonstrated defined objectives, a clear strategy, measurable success markers and will use an evidence-based approach.

Entrants can visit https://www.shire.com/patients/patient-advocacy/patient-group-award to download an application pack including an application form and full guidance on the process. The closing date for entries is 29 August 2016, and winners will be announced during European ADHD Awareness Month (October 2016).

Developed, funded and organised by Shire, the Excellence in ADHD Patient Group Awards are part of Shire’s patient-centric approach that provides support to people living with ADHD and their caregivers.

- END -

Download the PDF for the full release

About ADHD

ADHD is a common neurodevelopmental disorder in children and adolescents^1-3 and is recognised by the World Health Organization (WHO).⁴ Worldwide prevalence of ADHD is estimated to be between 5.29% and 7.1%, and just under 5% in Europe for children and adolescents (<18 years)^1,2 and 3.4% (range 1.0-7.3%) for adults aged 18-44.^5-9

For further information please contact:

Media
Charles Catalano	mailto:[email protected]	+1 781.266.3568

 

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

References

1. Polanczyk G, et al. The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis. Am J Psych. 2007;164:942–948.
2. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012; 9: 490-499.
3. American Psychiatric Association. Highlights of changes from DSM-IV-TR to DSM-5. Available at http://www.dsm5.org/Documents/changes%20from%20dsm-iv-tr%20to%20dsm-5.pdf [Last accessed June 2016].
4. International Classification of Diseases, 10th ed., (ICD-10). World Health Organization 2007:Chapter 5,F90. http://apps.who.int/classifications/icd10/browse/2010/en#/F90-F98. [Last accessed June 2016].
5. Simon V, et al. Prevalence And Correlates Of Adult Attention-Deficit Hyperactivity Disorder: Meta-Analysis. Br J Psychiatry 2009; 194: 204-211.
6. Kessler RC et al. The Prevalence And Correlates Of Adult ADHD In The United States: Results From The National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716-723.
7. Fayyad J, et al. Cross-National Prevalence And Correlates Of Adult Attention-Deficit Hyperactivity Disorder. Br J Psychiatry 2007; 190: 402-409.
8. de Zwaan M, et al. The Estimated Prevalence And Correlates Of Adult ADHD In A German Community Sample. Eur Arch Psychiatry Clin Neurosci 2012; 262: 79-86.
9. Polanczyk G, et al. ADHD In A Representative Sample Of The Brazilian Population: Estimated Prevalence And Comparative Adequacy Of Criteria Between Adolescents And Adults According To The Item Response Theory. Int J Methods Psychiatr Res 2010; 19: 177-184.